Edward Wu's questions to DAXOR (DXR) leadership • Q2 2022
Question
Edward Wu asked whether macroeconomic challenges, such as slowing GDP, were affecting Daxor's sales cycle for placing new devices. He also inquired about any supply chain disruptions or inflation-related cost issues the company has faced.
Answer
CEO & President Michael Feldschuh responded that in a cost-sensitive economic environment, Daxor's strong value proposition becomes more attractive to hospitals. He explained that the system's ability to shorten patient length-of-stay and serve as a lower-cost alternative to procedures like a right heart cath resonates with economically-focused hospital systems, supported by their partnership with MedAxiom. Regarding operations, he stated that Daxor has avoided significant supply chain problems for components due to its U.S.-based manufacturing but has experienced inflationary pressures related to rising staffing costs.